321 related articles for article (PubMed ID: 24619427)
1. Role of PET in lymphoma.
Gallamini A; Borra A
Curr Treat Options Oncol; 2014 Jun; 15(2):248-61. PubMed ID: 24619427
[TBL] [Abstract][Full Text] [Related]
2. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma.
Kobe C; Dietlein M; Hellwig D
Semin Nucl Med; 2018 Jan; 48(1):28-36. PubMed ID: 29195615
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET/CT in the management of lymphomas: current status and future directions.
El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
[TBL] [Abstract][Full Text] [Related]
4. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Blood; 2014 Nov; 124(23):3356-64. PubMed ID: 25428223
[TBL] [Abstract][Full Text] [Related]
5. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
6. PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas.
Barrington SF; Mikhaeel NG
Curr Hematol Malig Rep; 2016 Jun; 11(3):185-95. PubMed ID: 27095319
[TBL] [Abstract][Full Text] [Related]
7. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moskowitz CH; Zelenetz A; Schoder H
J Natl Compr Canc Netw; 2010 Mar; 8(3):347-52. PubMed ID: 20202464
[TBL] [Abstract][Full Text] [Related]
8. Risk- and response-adapted strategies for the management of Hodgkin lymphoma.
Remer M; Johnson PW
Chin Clin Oncol; 2015 Mar; 4(1):13. PubMed ID: 25841720
[TBL] [Abstract][Full Text] [Related]
9. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
10. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes.
Terasawa T; Nagai H
Leuk Lymphoma; 2009 Nov; 50(11):1750-2. PubMed ID: 19863179
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET in the clinical management of Hodgkin lymphoma.
Hutchings M; Eigtved AI; Specht L
Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of interim
Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
[TBL] [Abstract][Full Text] [Related]
14. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
[TBL] [Abstract][Full Text] [Related]
15. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
16. Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
Berriolo-Riedinger A; Becker S; Casasnovas O; Vander Borght T; Édeline V
Cancer Radiother; 2018 Sep; 22(5):393-400. PubMed ID: 30033076
[TBL] [Abstract][Full Text] [Related]
17. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
18. The role of FDG-PET scanning in assessing lymphoma in 2012.
Bodet-Milin C; Eugène T; Gastinne T; Bailly C; Le Gouill S; Dupas B; Kraeber-Bodéré F
Diagn Interv Imaging; 2013 Feb; 94(2):158-68. PubMed ID: 23295044
[TBL] [Abstract][Full Text] [Related]
19. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
Adams HJA; Kwee TC
Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]